VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ARDX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ARDXArdelyx, Inc.
$2.88$711M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksARDXP/E History

ARDX logoArdelyx, Inc. (ARDX) P/E Ratio History

Deep Value

Trading at -13.0x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2015–2015

Current P/E (TTM)
-13.0x
-108% vs 5Y avg
5Y Avg P/E
166.9x
Median 166.9x
5Y Percentile
0th
Lower end of range
PEG Ratio
N/A
TTM EPS$-0.22
Price$2.88
Earnings YieldN/A
EPS Growth (1Y)-52.9%
EPS Growth (5Y)N/A

Loading P/E history...

P/E Ratio Analysis

As of November 8, 2026, Ardelyx, Inc. (ARDX) trades at a price-to-earnings ratio of -13.0x, with a stock price of $2.88 and trailing twelve-month earnings per share of $-0.22.

The current P/E is 108% below its 5-year average of 166.9x. Over the past five years, ARDX's P/E has ranged from a low of 166.9x to a high of 166.9x, placing the current valuation at the 0th percentile of its historical range.

Compared to the Healthcare sector median P/E of 24.6x, ARDX trades at a 153% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.

Relative to the broader market, ARDX trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.

For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ARDX DCF Valuation Calculator →

Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.

ARDX Cross-Benchmark Valuation

How does the current P/E compare to sector peers and the broader market?

vs. Healthcare
-13.0vs24.6
-153%
Below Sector
vs. S&P 500
-13.0vs21.8
-159%
Below Market
PEG Analysis
N/A
P/E ÷ EPS Growth
Based on -53% EPS growth (1Y)

ARDX P/E vs Peers

Branded Specialty Pharma peers sorted by market cap

CompanyMarket CapP/E RatioPEG RatioEPS Growth (1Y)
INVA logoINVAInnoviva, Inc.
$1B7.10.69Best+817%
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$3B7.1Lowest-+10833%Best
PTGX logoPTGXProtagonist Therapeutics, Inc.
$8B27.7--148%
AMGN logoAMGNAmgen Inc.
$248B26.89.10+88%
ABBV logoABBVAbbVie Inc.
$515B49.9--1%

Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.

ARDX Historical P/E Data (2015–2015)

Quarterly P/E ratios calculated from closing price and TTM EPS

QuarterPeriod EndPriceTTM EPSP/E Ratiovs Avg
FY2015 Q2-$3.99$0.02166.9x+0%

Average P/E for displayed period: 166.9x

Export Data
Consensus & Technical Research Suite
Open ARDX Terminal

ARDX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

11+ years return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ARDX — Frequently Asked Questions

Quick answers to the most common questions about buying ARDX stock.

What is ARDX's P/E ratio?

Ardelyx, Inc. (ARDX) trailing twelve-month P/E ratio is -13.0x, based on TTM diluted EPS of $-0.22. The 5-year average P/E is 166.9x and the historical range spans 166.9x to 166.9x.

Is ARDX stock overvalued or undervalued?

ARDX trades at -13.0x P/E, below its 5-year average of 166.9x. At the 0th percentile of its historical range (166.9x–166.9x), the stock is priced at a discount to its own history.

Is ARDX stock expensive?

No, ARDX is not expensive on a historical basis. The current P/E of -13.0x is below the 5-year average of 166.9x and sits at the 0th percentile of its valuation range.

What is ARDX's historical P/E range?

Over the past 5 years, ARDX's P/E ratio has ranged from 166.9x to 166.9x, with a median of 166.9x and an average of 166.9x. The current P/E of -13.0x places the stock at the 0th percentile of this range. Full historical data spans 2015–2015.

How does ARDX's P/E compare to the S&P 500?

ARDX trades at -13.0x P/E versus the S&P 500 median of 21.8x. The 160% discount to the market suggests lower growth expectations or perceived higher risk.

How does ARDX's valuation compare to Healthcare peers?

Ardelyx, Inc. P/E of -13.0x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.

What is ARDX's PEG ratio?

ARDX PEG ratio is N/A, based on a P/E of -13.0x and EPS growth of -52.9%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.

What is ARDX's earnings yield?

ARDX earnings yield is N/A, the inverse of its -13.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.

ARDX P/E Ratio History (2015–2015)

Quarterly valuation multiple from closing price and trailing EPS

Current166.9x
Period Avg166.9x
Range166.9x - 166.9x
Change+0%
1 quartersJun 30, 2015 - Jun 30, 2015